JP2009526814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526814A5 JP2009526814A5 JP2008554764A JP2008554764A JP2009526814A5 JP 2009526814 A5 JP2009526814 A5 JP 2009526814A5 JP 2008554764 A JP2008554764 A JP 2008554764A JP 2008554764 A JP2008554764 A JP 2008554764A JP 2009526814 A5 JP2009526814 A5 JP 2009526814A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridazin
- yloxy
- aza
- bicyclo
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000002193 Pain Diseases 0.000 claims 7
- 230000036407 pain Effects 0.000 claims 7
- -1 pyridazinyloxy Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- GBCWWFFIDIIHRX-SFHVURJKSA-N (3r)-3-[6-(2-phenylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound O([C@@H]1C2CCN(C1)CC2)C(N=N1)=CC=C1C#CC1=CC=CC=C1 GBCWWFFIDIIHRX-SFHVURJKSA-N 0.000 claims 2
- GBCWWFFIDIIHRX-GOSISDBHSA-N (3s)-3-[6-(2-phenylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound O([C@H]1C2CCN(C1)CC2)C(N=N1)=CC=C1C#CC1=CC=CC=C1 GBCWWFFIDIIHRX-GOSISDBHSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- MUUUWBFOBOZNAB-INIZCTEOSA-N (3r)-3-[6-(2-thiophen-3-ylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound O([C@@H]1C2CCN(C1)CC2)C(N=N1)=CC=C1C#CC=1C=CSC=1 MUUUWBFOBOZNAB-INIZCTEOSA-N 0.000 claims 1
- UDYNGLMVVWUSRP-IBGZPJMESA-N (3r)-3-[6-[2-(4-methoxyphenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC(OC)=CC=C1C#CC(N=N1)=CC=C1O[C@@H]1C(CC2)CCN2C1 UDYNGLMVVWUSRP-IBGZPJMESA-N 0.000 claims 1
- MUUUWBFOBOZNAB-MRXNPFEDSA-N (3s)-3-[6-(2-thiophen-3-ylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound O([C@H]1C2CCN(C1)CC2)C(N=N1)=CC=C1C#CC=1C=CSC=1 MUUUWBFOBOZNAB-MRXNPFEDSA-N 0.000 claims 1
- UDYNGLMVVWUSRP-LJQANCHMSA-N (3s)-3-[6-[2-(4-methoxyphenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC(OC)=CC=C1C#CC(N=N1)=CC=C1O[C@H]1C(CC2)CCN2C1 UDYNGLMVVWUSRP-LJQANCHMSA-N 0.000 claims 1
- UNPROPIGVAWRMD-SFHVURJKSA-N 3-[2-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]ethynyl]aniline Chemical compound NC1=CC=CC(C#CC=2N=NC(O[C@@H]3C4CCN(CC4)C3)=CC=2)=C1 UNPROPIGVAWRMD-SFHVURJKSA-N 0.000 claims 1
- UNPROPIGVAWRMD-GOSISDBHSA-N 3-[2-[6-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]ethynyl]aniline Chemical compound NC1=CC=CC(C#CC=2N=NC(O[C@H]3C4CCN(CC4)C3)=CC=2)=C1 UNPROPIGVAWRMD-GOSISDBHSA-N 0.000 claims 1
- WTIWLMMJSGFSET-SFHVURJKSA-N 4-[2-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]ethynyl]aniline Chemical compound C1=CC(N)=CC=C1C#CC(N=N1)=CC=C1O[C@@H]1C(CC2)CCN2C1 WTIWLMMJSGFSET-SFHVURJKSA-N 0.000 claims 1
- WTIWLMMJSGFSET-GOSISDBHSA-N 4-[2-[6-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]ethynyl]aniline Chemical compound C1=CC(N)=CC=C1C#CC(N=N1)=CC=C1O[C@H]1C(CC2)CCN2C1 WTIWLMMJSGFSET-GOSISDBHSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000009849 deactivation Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- BATSDJUXECKTBY-FQEVSTJZSA-N n-[4-[2-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]ethynyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C#CC(N=N1)=CC=C1O[C@@H]1C(CC2)CCN2C1 BATSDJUXECKTBY-FQEVSTJZSA-N 0.000 claims 1
- BATSDJUXECKTBY-HXUWFJFHSA-N n-[4-[2-[6-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]ethynyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C#CC(N=N1)=CC=C1O[C@H]1C(CC2)CCN2C1 BATSDJUXECKTBY-HXUWFJFHSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600224 | 2006-02-16 | ||
| US77422006P | 2006-02-17 | 2006-02-17 | |
| PCT/EP2007/051399 WO2007093602A1 (en) | 2006-02-16 | 2007-02-13 | Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526814A JP2009526814A (ja) | 2009-07-23 |
| JP2009526814A5 true JP2009526814A5 (enExample) | 2010-04-02 |
Family
ID=42678793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554764A Abandoned JP2009526814A (ja) | 2006-02-16 | 2007-02-13 | 鏡像異性的に純粋なキヌクリジニルオキシピリダジン、及びニコチン性アセチルコリン受容体リガンドとしてのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100227869A1 (enExample) |
| EP (1) | EP1987029B1 (enExample) |
| JP (1) | JP2009526814A (enExample) |
| AT (1) | ATE455114T1 (enExample) |
| DE (1) | DE602007004307D1 (enExample) |
| WO (1) | WO2007093602A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6262265A (ja) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | 復水器自動検査補修システム |
| JP2013526546A (ja) * | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| SG192078A1 (en) | 2011-02-03 | 2013-08-30 | Lupin Ltd | Pyrrole derivatives used as modulators of alpha7 nachr |
| AP3649A (en) | 2011-02-23 | 2016-03-18 | Lupin Ltd | Heteroaryl derivatives as alpha7 nachr modulators |
| BR112013025128A2 (pt) | 2011-03-31 | 2017-02-14 | Lupin Ltd | derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson |
| US8946432B2 (en) | 2011-07-05 | 2015-02-03 | Lupin Limited | Biaryl derivatives as nAChR modulators |
| US9388196B2 (en) | 2012-03-06 | 2016-07-12 | Lupin Limited | Thiazole derivatives as alpha 7 nAChR modulators |
| EP2945936A1 (en) | 2012-11-12 | 2015-11-25 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| JP2016508159A (ja) * | 2013-01-15 | 2016-03-17 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体アゴニストの使用 |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| US9617211B2 (en) | 2013-01-16 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| WO2014141091A1 (en) | 2013-03-13 | 2014-09-18 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| CA2913987A1 (en) | 2013-06-17 | 2014-12-24 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220581D0 (en) * | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| US7241773B2 (en) * | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
| DE602005025902D1 (de) * | 2004-10-15 | 2011-02-24 | Neurosearch As | Neue azabizyklische arylderivate und medizinische verwendung damit |
-
2007
- 2007-02-13 EP EP07704570A patent/EP1987029B1/en not_active Not-in-force
- 2007-02-13 AT AT07704570T patent/ATE455114T1/de not_active IP Right Cessation
- 2007-02-13 US US12/160,402 patent/US20100227869A1/en not_active Abandoned
- 2007-02-13 WO PCT/EP2007/051399 patent/WO2007093602A1/en not_active Ceased
- 2007-02-13 DE DE602007004307T patent/DE602007004307D1/de active Active
- 2007-02-13 JP JP2008554764A patent/JP2009526814A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526814A5 (enExample) | ||
| JP2009538870A5 (enExample) | ||
| JP2009538869A5 (enExample) | ||
| EP1532144B1 (en) | quinuclidine derivatives and their use | |
| JP2009537599A5 (enExample) | ||
| JP2005538187A5 (enExample) | ||
| JP2008517032A5 (enExample) | ||
| JP2005524713A5 (enExample) | ||
| IL180309A (en) | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of psychotic and neurodegenerative disorders | |
| JP2012526736A5 (enExample) | ||
| JP2012526735A5 (enExample) | ||
| JP2008530172A5 (enExample) | ||
| US20100184775A1 (en) | Organic compounds | |
| JP2009526814A (ja) | 鏡像異性的に純粋なキヌクリジニルオキシピリダジン、及びニコチン性アセチルコリン受容体リガンドとしてのその使用 | |
| JP2009538866A5 (enExample) | ||
| EP1966209B1 (en) | [ 1h- indol- 5 -yl) -heteroaryloxy] - (1-aza-bicyclo [3.3.1] nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders | |
| JP2009526776A5 (enExample) | ||
| JP2007520525A5 (enExample) | ||
| JP2005530814A5 (enExample) | ||
| JP2007530635A5 (enExample) | ||
| EP1713809B1 (en) | Dimeric azacyclic compounds and their use | |
| JP2006503062A5 (enExample) | ||
| JP2009526024A5 (enExample) | ||
| RU2010114662A (ru) | Новые производные 1,4-диазабицикло(3.2.2)нонилпиримидина и их медицинское применение | |
| JP2007538046A5 (enExample) |